文献速递慢性肾脏病肾血管病与高血压

血压与CKD进展的关联:KNOW-CKD研究

Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study.
PubMed 文献 · Am J Kidney Dis · 2021-01-11

该前瞻性观察性队列研究纳入2044例韩国CKD患者,随访7472人年,发现基线及时间更新收缩压升高与复合肾脏结局风险增加相关,且收缩压较舒张压与肾脏不良结局的关联更强。

要点

  • 收缩压≥140 mmHg与复合肾脏结局风险显著增加相关。
  • 时间更新收缩压较基线收缩压与结局关联更明显。
  • 收缩压较舒张压与肾脏不良结局关联更强。

核心结论

  • CKD患者中较高的收缩压和舒张压水平与反映CKD进展的复合肾脏结局风险增加相关。
  • 收缩压与不良肾脏结局的关联强于舒张压。

研究设计与样本

  • 前瞻性观察性队列研究,纳入韩国CKD患者队列(KNOW-CKD)2044例参与者。
  • 暴露为基线和时间更新的收缩压与舒张压。
  • 结局为eGFR较基线下降≥50%或新发肾脏替代治疗的复合肾脏结局。
  • 分别采用多变量病因特异性风险模型和边际结构模型分析基线和时间更新血压。

主要发现

  • 随访7472人年期间,473例(23.1%)发生主要复合肾脏结局,发病率为63.3/1000患者年。
  • 与基线收缩压<120 mmHg相比,120-129、130-139和≥140 mmHg的风险比分别为1.10(95%CI 0.83-1.44)、1.20(95%CI 0.93-1.59)和1.43(95%CI 1.07-1.91)。
  • 时间更新收缩压模型中,相应风险比分别为1.31(95%CI 0.98-1.75)、1.59(95%CI 1.16-2.16)和2.29(95%CI 1.69-3.11)。
  • 时间更新舒张压而非基线舒张压与复合肾脏结局显著相关。
  • 与收缩压<120 mmHg患者相比,收缩压较高者eGFR下降斜率更陡。

临床怎么用

  • 在CKD患者管理中,应重视收缩压控制以降低肾脏不良结局风险。
  • 动态监测收缩压变化可能比单次基线血压更能反映肾脏进展风险。

局限性

  • 观察性设计。
  • 存在未测量的混杂因素。
  • 仅使用诊室血压。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Optimal blood pressure (BP) control is a major therapeutic strategy in the management of chronic kidney disease (CKD). We studied the association between BP and adverse kidney outcomes within a diverse cohort of Koreans with CKD. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: 2,044 participants from the Korean Cohort Study for Outcomes in Patients With CKD (KNOW-CKD). EXPOSURES: Baseline and time-updated systolic BP (SBP) and diastolic BP (DBP). OUTCOME: A composite kidney outcome of a≥50% decline in estimated glomerular filtration rate (eGFR) from the baseline value or incident kidney replacement therapy. ANALYTICAL APPROACH: Multivariate cause-specific hazards models and marginal structural models were fitted for baseline and time-updated BP, respectively. RESULTS: During 7,472 person-years of follow-up, the primary composite kidney outcome occurred in 473 participants (23.1%), an incidence rate of 63.3 per 1,000 patient-years. Compared with baseline SBP<120mm Hg, the hazard ratios (HRs) for 120-129, 130-139, and≥140mm Hg were 1.10 (95% CI, 0.83-1.44), 1.20 (95% CI, 0.93-1.59), and 1.43 (95% CI, 1.07-1.91), respectively. This association was more evident in the model with time-updated SBP, for which the corresponding HRs were 1.31 (95% CI, 0.98-1.75), 1.59 (95% CI, 1.16-2.16), and 2.29 (95% CI, 1.69-3.11), respectively. In the analyses of DBP, we observed that time-updated DBP but not baseline DBP was significantly associated with the composite kidney outcome. Compared to patients with SBP<120mm Hg, patients with higher SBP had steeper slopes of eGFR decline. In the model including both SBP and DBP, only SBP was significantly associated with the composite kidney outcome. LIMITATIONS: Observational design, unmeasured confounders, and use of office BPs only. CONCLUSIONS: In patients with CKD, higher SBP and DBP levels were associated with a higher risk of a composite kidney outcome reflecting CKD progression. SBP had a greater association with adverse kidney outcomes than DBP.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lee JY, Park JT, Joo YS, et al. Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study. Am J Kidney Dis. 2021. PMID: 33444666. doi:10.1053/j.ajkd.2020.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。